


WHAT IS CLAIMED IS:

1. A sapogenin according to the formula:



10

wherein R<sub>1</sub> is H, glc or glc<sup>1-2</sup> glc, R<sub>2</sub> is H or OH, R<sub>3</sub> is H or OH; and when R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are H, there are double bonds at positions 20(21) and 24(25); and when R<sub>1</sub> is H, R<sub>2</sub> is OH and R<sub>3</sub> is OH, there are double bonds at positions 20(22) and 25(26); and when R<sub>1</sub> is H, R<sub>2</sub> is OH and R<sub>3</sub> is H, there are double bonds at positions 20(22) and 24(25); and when R<sub>1</sub> is glc, R<sub>2</sub> is H and R<sub>3</sub> is H, there are double bonds at positions 20(21) and 24(25); and when R<sub>1</sub> is glc<sup>1-2</sup>glc, R<sub>2</sub> is H and R<sub>3</sub> is H, there are double bonds at positions 20(22) and 24(25); and pharmaceutically acceptable compositions incorporating said sapogenins.

15

20

2. A sapogenin as claimed in claim 1 wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are H, and there are double bonds at 20(21) and 24(25).

25

3. A sapogenin as claimed in claim 1 wherein R<sub>1</sub> is H, R<sub>2</sub> and R<sub>3</sub> are OH, and there are double bonds at 20(22) and 25(26).

4. A sapogenin as claimed in claim 1 wherein R<sub>1</sub> is H, R<sub>2</sub> is OH and R<sub>3</sub> is H, and there are double bonds at 20(22) and 24(25).



30

5. A sapogenin as claimed in claim 1 wherein R<sub>1</sub> is glc, R<sub>2</sub> and R<sub>3</sub> are H, and there are double bonds at 20(21) and 24(25).

7. The use of a sapogenin according to the formula recited in claim 1 in treating cancer cells in a human being suffering from cancer, comprising killing cancer cells, inducing apoptosis in cancer cells, or inhibiting multiplication of cancer cells, or any combination thereof.


8. The use of a sapogenin according to the formula recited in claim 1 in  
10 treating multi-drug resistant cancer cells (MDR) in a human being suffering from  
cancer, comprising using the sapogenins either singly, or in combination with one  
another, or in combination with other chemotherapy agents.

9. A sapogenin according to the formula:



11. A sapogenin according to the formula:


5



PBM-110


102

12. A sapogenin according to the formula:



PAN-20

- 10 13. A sapogenin according to the formula:



PAN-30

102

601220 2000660

Sub P  
5 14. A method of treating cancer in human beings or other animals suffering from cancer comprising administering to said human beings a therapeutically effective amount of a composition comprising one or more of PAM-120, PBM-100 and PBM-110.

10 15. A method of treating cancer in human beings or other animals suffering from cancer comprising administering to said human beings a therapeutically effective amount of a composition comprising one or more of PAN-20 and PAN-30.

Sub B  
PBM  
15 16. The cancer-treatment method of claim 14 comprising a pharmaceutically effective amount of PAM-120, PAM-100 and PBM-110 with or without one or more pharmaceutically acceptable carriers, and one or more chemotherapeutic agents.

20 17. The cancer-treatment method of claim 14, wherein the active ingredient is administered in a dosage of between 5 micrograms to 50 grams per kg body weight per day.

25 18. The cancer-treatment method of claim 14, wherein the active ingredient is administered in a dosage of between 50 micrograms to 5 grams per kg body weight per day.

30 19. The cancer-treatment method of claim 17, wherein the form of the composition is selected from the group consisting of an orally administrable form, an injectable form, and a topically applicable form.

35 20. The cancer-treatment method of claim 19, wherein the orally administrable form is selected from the group consisting of a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit, a syrup and a lemonade.

21. The cancer-treatment method of claim 19, wherein the injectable form is selected from the group consisting of a liquid, a suspension and a solution.

22. The cancer-treatment method of claim 19, wherein the topically applicable

form is selected from the group consisting of a drop, a paste, an ointment, a liquid, a powder, a plaster, a suppository, an aerosol, a liniment, a lotion, an enema and an emulsion.

5 23. The cancer-treatment method of claims 14 or 15, wherein the composition is administered to human beings who are receiving one or more other anti-cancer treatments.

10 24. The cancer-treatment method in claims 14 or 15, wherein the composition is formulated with one or more other anti-cancer agents, for additive treatment effects, or synergistic treatment effects on multi-drug resistance cancers or any other cancer type.

15 25. A process of preparing a sapogenin as claimed in claim 1 which comprises producing a ginsenoside extract from plants selected from the group consisting of panax ginseng, panax quinquefol and panax notoginseng, or a sapogenin source from some other plant, and proceeding according to the following steps:

- 20 (a) mixing the ginsenoside extract with water;
- (b) (i) mixing the ginsenoside extract and water with a short-chain (1-5 carbon) alkali-metal alcoholate solution or a hydroxide-ethanol solution to produce a mixture; and
- (ii) placing the resultant mixture in a reaction tank so that the resultant mixture can undergo chemical reactions under required high temperature and high pressure; or
- 25 (c) (i) alternatively, mixing the ginsenosides extract with ethanol;
- (ii) mixing the extract and ethanol with alkali-metal alcoholates solution to produce a mixture, and
- (iii) placing the resultant mixture in a reaction tank so that the resultant mixture can undergo chemical reactions under required high temperature and high pressure;
- 30 (d) after the reaction is completed, collecting an intermediate product of a mix of ginsenosides and sapogenins from the ethanol mixture; and
- (e) separating the desired sapogenins from the intermediate saponin-sapogenin mixture by silica-gel-column chromatography.
- 35

26. A process as claimed in claim 25 wherein the alkali metal can be

potassium or sodium.

27. A process as claimed in claim 25 wherein the hydroxide can be sodium hydroxide or potassium hydroxide.

5

28. A process as claimed in claim 25 wherein the alkali-metal alcoholates solution or the concentration of hydroxide-ethanol solution is 5-50% (W/V).

10

29. A process as claimed in claim 25 wherein the ethanol has 1-5 carbon atoms.

30. The process as claimed in claim 25 wherein the temperature of the reaction tank is between 150-300°C and the reaction pressure is between 2.5-8.4 MPa.

15

31. A process of preparing a sapogenin as claimed in claim 1 which comprises producing a ginsenoside extract from plants selected from the group consisting of panax ginseng, panax quinquefol and panax notoginseng, and proceeding according to the following steps:

20

- (a) mixing the ginsenoside extract with water;
- (b) mixing the ginsenoside extract and water with a short-chain (1-5 carbon) alkali-metal alcoholate solution or a hydroxide-ethanol solution to produce a mixture; and
- (c) placing the resultant mixture in a reaction tank so that the resultant mixture can undergo chemical reactions under required high temperature and high pressure; or
- (d) after the reaction is completed, collecting an intermediate product of a mix of ginsenosides and sapogenins from the ethanol mixture; and
- (e) separating the desired sapogenins from the intermediate saponin-sapogenin mixture by silica-gel-column chromatography.

25

30

35

32. A process of preparing a sapogenin as claimed in claim 1 which comprises producing a ginsenoside extract from plants selected from the group consisting of panax ginseng, panax quinquefol and panax notoginseng, and proceeding according to the following steps:

- (a) mixing the ginsenoside extract with water;
- (b) alternatively, mixing the ginsenosides extract with ethanol;

- 

1967		1968		1969		1970		1971		1972		1973		1974		1975		1976		1977		1978		1979		1980		1981		1982		1983		1984		1985		1986		1987		1988		1989		1990		1991		1992		1993		1994		1995		1996		1997		1998		1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016		2017		2018		2019		2020		2021		2022		2023		2024		2025		2026		2027		2028		2029		2030		2031		2032		2033		2034		2035		2036		2037		2038		2039		2040		2041		2042		2043		2044		2045		2046		2047		2048		2049		2050		2051		2052		2053		2054		2055		2056		2057		2058		2059		2060		2061		2062		2063		2064		2065		2066		2067		2068		2069		2070		2071		2072		2073		2074		2075		2076		2077		2078		2079		2080		2081		2082		2083		2084		2085		2086		2087		2088		2089		2090		2091		2092		2093		2094		2095		2096		2097		2098		2099		2100		2101		2102		2103		2104		2105		2106		2107		2108		2109		2110		2111		2112		2113		2114		2115		2116		2117		2118		2119		2120		2121		2122		2123		2124		2125		2126		2127		2128		2129		2130		2131		2132		2133		2134		2135		2136		2137		2138		2139		2140		2141		2142		2143		2144		2145		2146		2147		2148		2149		2150		2151		2152		2153		2154		2155		2156		2157		2158		2159		2160		2161		2162		2163		2164		2165		2166		2167		2168		2169		2170		2171		2172		2173		2174		2175		2176		2177		2178		2179		2180		2181		2182		2183		2184		2185		2186		2187		2188		2189		2190		2191		2192		2193		2194		2195		2196		2197		2198		2199		2200		2201		2202		2203		2204		2205		2206		2207		2208		2209		2210		2211		2212		2213		2214		2215		2216		2217		2218		2219		2220		2221		2222		2223		2224		2225		2226		2227		2228		2229		2230		2231		2232		2233		2234		2235		2236		2237		2238		2239		2240		2241		2242		2243		2244		2245		2246		2247		2248		2249		2250		2251		2252		2253		2254		2255		2256		2257		2258		2259		2260		2261		2262		2263		2264		2265		2266		2267		2268		2269		2270		2271		2272		2273		2274		2275		2276		2277		2278		2279		2280		2281
------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------